Jan 19, 2023 6:47am EST NRx Pharmaceuticals Provides Progress Update on Interactions with the FDA regarding Path to NDA Submission for NRX-101
Jan 05, 2023 6:47am EST NRx Pharmaceuticals to Present Scientific Update at the 6th Annual Sachs Associates Neuroscience Innovation Forum in Conjunction with the 2023 J.P. Morgan Healthcare Conference
Jan 03, 2023 6:47am EST NRx Pharmaceuticals Initiates Phase 3 Trial Treating Patients with Bipolar Depression with Acute Suicidality - First Clinical Site Contracted
Dec 20, 2022 1:30am EST Relief Therapeutics Holding SA and NRx Pharmaceuticals, Inc. Announce Close of Definitive Settlement Agreements
Dec 05, 2022 6:47am EST NRx Pharmaceuticals Announces the Appointment of Carrie M. Carretta, PhD, APN-BC, AHN-BC, PMHNP, Senior Vice President of Clinical Development and Medical Affairs
Nov 14, 2022 6:47am EST NRx Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update
Nov 14, 2022 1:15am EST Relief Therapeutics Holding SA and NRx Pharmaceuticals, Inc. Announce Execution of Definitive Settlement Agreements
Nov 10, 2022 6:47am EST NRx Pharmaceuticals to Report Third Quarter 2022 Results on November 14, 2022
Nov 09, 2022 6:47am EST NRx Pharmaceuticals Produces First Phase 3-stage NRX-101 Drug Made Using Commercial Process
